Firm Wire items are announcements made by the firms themselves. The desk confirms that the announcement was published and reproduces its factual content. It does not verify the claims in it, and publication is not an endorsement.
Goodwin says it advised City Therapeutics on its $200 million IPO pricing
Goodwin said its life sciences team advised City Therapeutics on pricing an upsized initial public offering expected to raise approximately $200 million before expenses. The firm said City is developing RNA interference therapies and that all shares in the offering are being sold by the company.
Key points
- Goodwin reported 11,111,111 shares priced at $18 each.Goodwin
- The firm said underwriters have a 30-day option to purchase up to 1,666,666 additional shares.Goodwin
- Goodwin identified CITY-FXI, CITY-RBP4 and CITY-TFR2 as the company’s lead development programs.Goodwin
- The firm said Sarah Ashfaq, Karin Yoo, Haylee Brown, Adam DiTullio and Kingsley Taft led its corporate team.Goodwin